List of Atelvia drug patents
Atelvia is owned by Apil.
Atelvia contains Risedronate Sodium.
Atelvia has a total of 3 drug patents out of which 0 drug patents have expired.
Atelvia was authorised for market use on 08 October, 2010.
Atelvia is available in tablet, delayed release;oral dosage forms.
Atelvia can be used as treatment of osteoporosis in postmenopausal women.
The generics of Atelvia are possible to be released after 09 January, 2028.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8246989 | APIL | Dosage forms of bisphosphonates |
Jan, 2026
(2 years from now) | |
| US7645460 | APIL | Dosage forms of risedronate |
Jan, 2028
(4 years from now) | |
| US7645459 | APIL | Dosage forms of bisphosphonates |
Jan, 2028
(4 years from now) | |
Drugs and Companies using RISEDRONATE SODIUM ingredient
Market Authorisation Date: 08 October, 2010
Treatment: Treatment of osteoporosis in postmenopausal women
Dosage: TABLET, DELAYED RELEASE;ORAL
ATELVIA family patents
19
United States
7
Korea, Republic of
5
Japan
4
China
4
European Union
3
Australia
3
Canada
3
New Zealand
3
Spain
3
Portugal
2
Israel
2
Denmark
2
Russia
2
Poland
2
Morocco
2
Norway
2
Mexico
2
San Marino
2
Brazil
2
Argentina
2
Taiwan
1
India
1
Croatia
1
Peru
1
Malaysia
1
Austria
1
Cyprus
1
Hong Kong
1
Germany
1
Slovenia
1
South Africa
1
RS
1
Hungary
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic